Clinical Trials Sponsored by Indivior Inc.

Total 35390 results

Indivior Inc.

Completed

Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder

Healthy Volunteer | Opioid-use Disorder

United States
Indivior Inc.

Completed

Survey of Buprenorphine Use Among "Out of Care" Population in France (P04933)(COMPLETED)

Drug Addiction
Indivior Inc.

Terminated

An Observational Study of Environmental and Socioeconomic Factors in Opioid Recovery - Long Term (RECOVER-LT)

Opioid Use Disorder

United States
Indivior Inc.

Completed

Buprenorphine-Fentanyl Interaction Study

Healthy | Opioid Use

Netherlands
Indivior Inc.

Completed

An Observational Study of Environmental and SocioEconomic Factors in Opioid Recovery (RECOVER®)

Opioid-use Disorder | Opioid-related Disorders

United States
Indivior Inc.

Completed

Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder

Opioid Use Disorder | Opioid-related Disorders

United States
Indivior Inc.

Completed

Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder

Opioid Use Disorder

United States
Indivior Inc.

Completed

A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder

Alcohol Use Disorder

United States
Indivior Inc.

Completed

Transfer of Subjects From Subutex/Suboxone to RBP-6300

Opioid Related Disorder

Austria, Czech Republic, Germany, Sweden
Indivior Inc.

Completed

A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse (RBP-8000)

Opioid Dependence | Cocaine Dependence | Opioid Related Disorders

United States
Indivior Inc.

Completed

Single-dose, Study of RBP-6000 in Opioid Dependent Individuals

Opioid Use Disorder

United States
Indivior Inc.

Completed

First in Man Study of Safety, Tolerability and PK Profile of RBP-7000

Schizophrenia

United States
Indivior Inc.

Completed

Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME") (RIME)

Opioid Dependency

France
Indivior Inc.

Not yet recruiting

Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

Opioid Use Disorder
Indivior Inc.

Recruiting

Evaluating the SUBLOCADE Treatment Exit Strategy

Opioid Use Disorder

United States, Canada
Indivior Inc.

Recruiting

SUBLOCADE Long-term Outcomes

Opioid Use Disorder

United States, Canada
Indivior Inc.

Completed

Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)

Drug Abuse | Opiate Dependence | Opiate-related Disorders
Indivior Inc.

Completed

SUBLOCADE Rapid Initiation Study

Opioid-use Disorder

United States
Indivior Inc.

Completed

Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone

Schizophrenia

United States
Indivior Inc.

Completed

SUBLOCADE Rapid Initiation Extension Study

Opioid Use Disorder, Moderate | Opioid Use Disorder, Severe

United States
Indivior Inc.

Completed

Study of a Novel Subcutaneous Depot Formulation of Buprenorphine

Opioid-use Disorder

United Kingdom
Indivior Inc.

Completed

Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients

Schizophrenia

United States
Indivior Inc.

Completed

Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia

Schizophrenia

United States
Indivior Inc.

Completed

Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine

Opioid Dependence | Opioid Related Disorders

United States
Indivior Inc.

Completed

Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population

Opioid Dependence

United States
Indivior Inc.

Completed

PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia

Schizophrenia

United States
Indivior Inc.

Completed

Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects

Hepatic Impairment | Hepatic Failure | Chronic Hepatitis C Infection With Hepatic Coma

United States
Indivior Inc.

Completed

A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED)

Opiate Dependence | Drug Dependence
Indivior Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease

GERD

United States
Indivior Inc.

Completed

Single Ascending Dose Study of RBP-7000

Schizophrenia

United States
Indivior Inc.

Completed

Treatment of Opioid Dependent Patients With Suboxone: Acceptability & Safety Data From Real Life Scenario (Study P05603)

Opioid-Related Disorders | Drug Abuse | Opiate Dependence
Indivior Inc.

Completed

Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations

Opioid Use Disorder

United States
Indivior Inc.

Active, not recruiting

Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users

Moderate to Severe Opioid-use Disorder

United States, Canada
Indivior Inc.

Completed

Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants

Opioid Use Disorder

United States
Indivior Inc.

Completed

Study of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults

Healthy

United States
Indivior Inc.

Completed

Observational Study of Misuse of High Dose Buprenorphine (Subutex® or Generic) in Opiate-Addicted Patients in France (Study P05186AM1)(COMPLETED) (OPUS R)

Naloxone | Drug Abuse | Opiate Dependence | Buprenorphine | Opiate-related Disorders
Indivior Inc.

Completed

Evaluation of Long-term Buprenorphine Plasma Exposure

Opioid-use Disorder

United States
Indivior Inc.

Completed

Open-Label Treatment Extension Study

Opioid Use Disorder | Opioid-related Disorders

United States
Indivior Inc.

Completed

Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy

Schizophrenia

United States
Indivior Inc.

Completed

Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder

Opioid Use Disorder

United States
Indivior Inc.

Completed

Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects

Opioid Related Disorder

United States
Indivior Inc.

Completed

A Phase 1 Bioavailability Study of Arbaclofen Placarbil Modified Release Formulations in Healthy Volunteers

Healthy Volunteers

United Kingdom
Indivior Inc.

Completed

Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone

Opioid-related Disorders

United States
Indivior Inc.

Completed

Acceptability and Safety of Switching From Subutex or Other Opioid Drug Dependence Therapy to Suboxone (NIS P05444)

Opioid-Related Disorders | Drug Abuse | Opiate Dependence

Austria
Indivior Inc.

Completed

Single Ascending Dose Study of RBP-6000 (SAD)

Opioid Use Disorder

United States
Indivior Inc.

Completed

Safety and Tolerability of Buprenorphine/Naloxone Film Strips

Opioid-Related Disorders

United States
Indivior Inc.
Reckitt Benckiser LLC

Completed

Study of Two Formulations of Buprenorphine HCl in Opioid-dependent Subjects on Buprenorphine Maintenance Therapy (Study P04451) (COMPLETED)

Opioid Dependency
Indivior Inc.
AESCA Pharma GmbH

Terminated

Buprenorphine Versus Methadone Maintenance in Hepatitis C Patients Receiving Peg-Intron and Rebetol (Study P04279)(TERMINATED)

Hepatitis C, Chronic
University of California, Los Angeles
Indivior Inc.

Completed

Randomized, Double-Blind Cross-Over Trial Of Buprenorphine and Low-Dose Naloxone Versus Buprenorphine

Pain

United States
BC Centre on Substance Use
Indivior Inc.

Recruiting

Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose (FASTER-BUP)

Opioid Overdose | Opioid-Use Disorder

Canada

3

Subscribe